Latest News

In palliative care, AI may serve as a supportive tool rather than a replacement of clinical judgment, said Ram Prakash Thirugnanasambandam, MBBS.

According to investigators of the phase 3 SCOT trial, most patients with colon and rectal cancer should be receiving only 3 months of adjuvant treatment.

Artificial intelligence may be used in CT scans to help detect early-stage disease in at-risk patients undergoing screening for cancer.

Intensive surveillance and surgical resection for hepatic metastases from uveal melanoma improved long-term remission in a retrospective study.

Kathie-Ann Joseph, MD, MPH, FACS, explored evolving surgical strategies for inflammatory breast cancer and phyllodes tumors.

One of the lesser-known costs of undergoing cancer treatment is the loss of work opportunities, according to Loretta Nastoupil, MD.

Soumen Das, MBBS, MS, FACS, details how the BC-RADS-2 study standardizes clinical breast examinations to combat diagnostic delays and improve early-stage detection in low-resource oncology settings.

Pembrolizumab administered before surgery in patients with desmoplastic melanoma led to high pathologic complete response rates in the SWOG S1512 trial.

Soumen Das, MS, FACS, discusses the BCRADS-2 study, a validated clinical scoring system designed to standardize breast cancer triage and downstage palpable lesions in low- and middle-income countries.

The median progression-free survival was significantly higher with donor vs placebo fecal microbiota transplantation in this RCC population.

In the phase 1/2 ReFocus trial, lirafugratinib demonstrated a median PFS of 11.3 months in the chemotherapy pretreated, FGR inhibitor-naïve CCA population.

Soumen Das, MBBS, MS, FACS, discussed the BC-RADS-2 study, a community-integrated approach to standardizing breast cancer detection in low-resource settings through a structured clinical reporting and data system.

PSMA-PET could be considered in selective cases, given its modest sensitivity and prognostic value in intermediate-risk prostate cancers.

Investigators are currently assessing QTX-2101 among patients with acute promyelocytic leukemia in a phase 3 trial.

Phase 2 PFLT-PC data revealed no significant disease was seen in 84% of patients treated with cooled laser focal therapy for prostate cancer at 3 months.

In the PATINA trial, adding palbociclib to maintenance therapy significantly improved progression-free survival in patients with HR+, HER2+ breast cancer.

The FDA has assigned a Prescription Drug User Fee Act date of November 14, 2026, for the ivonescimab-based combination.

The developer now plans to initiate a first-in-human clinical trial among patients with recurrent high-grade glioma.

Approval of the larger vial size may offer more dosing flexibility for pediatric and adult patients with T-cell ALL or LBL.

A new guideline from ASCO and Ontario Health conditionally recommends the use of daratumumab for patients with high-risk smoldering multiple myeloma.

Any-grade treatment-emergent immune-mediated AEs occurred in 22% of patients with early-stage lymphoma treated with the ADC-based regimen.

People who consumed 14 or more drinks per week experienced a higher risk of colorectal cancer compared with those who consumed one or fewer drinks.

Findings from the phase 1b/2 TENACITY-01 trial, which is assessing CTD402 monotherapy in these hematologic malignancies, supported the agency’s decision.

Adding ANPEP and PIGR to a biomarker blood panel of CA19-9 and THBS2 significantly improved the detection rate of any-stage pancreatic cancer.

Results of 9 patients with metastatic breast cancer dosed with Bria-IMT have shown sustained survival.

The FDA held a Type B meeting regarding the use of d3-T, a form of testosterone, and the risk of developing breast cancer in women.

Researchers have generated a high-resolution spatial atlas of the human gastrointestinal tract in aGVHD, revealing epithelial disruption and unexpected immune cell patterns that reshape how the disease is understood.

Findings from the phase 1/2 BRUIN trial support the Notice of Compliance with conditions for pirtobrutinib in this relapsed/refractory disease population.

Data from the phase 3 CEPHEUS trial support the approval of the daratumumab-based regimen among patients with newly diagnosed multiple myeloma.

Following 2 prior CRLs from the FDA for the rivoceranib plus camrelizumab regimen in frontline HCC, the developer has again submitted an NDA to the FDA.

Data from the phase 3 PEAK trial demonstrate that bezuclastinib plus sunitinib may be favorable vs sunitinib alone in certain patients with GISTs.